Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | LITESPARK-005: subgroup analysis of belzutifan efficacy in ccRCC

Guillermo De Velasco • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Belzutifan Everolimus
LITESPARK-005

Guillermo de Velasco, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, explores findings from the Phase III LITESPARK-005 study (NCT04195750) of belzutifan versus everolimus in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed on anti–PD-(L)1 and VEGF-targeted therapy. Results show significant improvements in progression-free survival and objective response rate with belzutifan, consistent across subgroups based on baseline disease characteristics and tumor burden. However, no overall survival benefit was observed. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guillermo De Velasco

Assessing the potential role of belzutifan in earlier lines of RCC treatment
0:48
Assessing the potential role of belzutifan in earlier lines of RCC treatment
Guillermo De Velasco • 13 Feb 2025
SOGUG-AUREA: split-dose cisplatin with atezolizumab in la/mUC
1:48
SOGUG-AUREA: split-dose cisplatin with atezolizumab in la/mUC
Guillermo De Velasco • 13 Feb 2025
Updates on the CABOPRE Phase II trial in patients with metastatic renal cell carcinoma
2:40
Updates on the CABOPRE Phase II trial in patients with metastatic renal cell carcinoma
Guillermo De Velasco • 27 Sep 2021
First-line treatment decision making for patients with RCC
2:21
First-line treatment decision making for patients with RCC
Guillermo De Velasco • 27 Sep 2021

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals